A Retrospective Observational Study of Adverse Drug Reactions (ADR) Reported to ADR Monitoring Centre from 2010 to 2020.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
Akila Srinivasan, Sandhiya Selvarajan, Santhosh Shivabasappa, Arunmozhy Singaravelu
{"title":"A Retrospective Observational Study of Adverse Drug Reactions (ADR) Reported to ADR Monitoring Centre from 2010 to 2020.","authors":"Akila Srinivasan, Sandhiya Selvarajan, Santhosh Shivabasappa, Arunmozhy Singaravelu","doi":"10.2174/0115748863317987241015034413","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Adverse Drug Reactions (ADR) are one of the essential causes of hospital admissions and pose a significant clinical and economic burden on the healthcare system. The Adverse Drug Reaction Monitoring Centre (AMC) in JIPMER functioning under the Pharmacovigilance Programme of India (PvPI) plays a vital role in ensuring medication safety by routinely detecting and monitoring ADRs. Hence, this study aimed to assess the characteristics of ADR reported from 2010 to 2020 in AMC JIPMER and to detect signals, if any.</p><p><strong>Objectives: </strong>To study the characteristics of Adverse Drug Reactions (ADR) reported to a regional ADR monitoring center from 2010 to 2020 and to detect signals of disproportionate reporting (SDRs) if any from the reported ADRs.</p><p><strong>Materials and methods: </strong>A total of 6007 ADR reports with a single suspect drug were included for analysis from 2010 to 2020. The characteristics of these reports, including patient's age and gender, Number and percentage of ADRs, the causality of ADR using WHO UMC (World Health Organization-Uppsala Monitoring Scale), the seriousness of the ADR, and outcome were collected from the ADR reports. MedDRA (Medical Dictionary for Regulatory Activities) Preferred Terms (PT) were used to classify adverse drug reactions. Causality analysis using the Naranjo Algorithm and Preventability using Modified Schumock and Thornton criteria were performed for the ADRs. The number and percentage of severe ADRs were analyzed. The System Organ class of all the ADRs was enumerated. ADRs not mentioned in the US FDA (United States Food and Drug Administration) product label (unlabelled reactions) were documented. Unlabeled reactions with ≥3 ADR reports were included for signal detection by disproportionality analysis.</p><p><strong>Results: </strong>Antineoplastic drugs, followed by antimicrobials, anticonvulsants, Anti snake venom, and NSAID were the most common drugs implicated in ADRs. Skin and subcutaneous tissue disorders were the most common System Organ Class (SOC) involved in the ADRs. Among the 6007 reports, 19.2% were serious ADRs. Most of the ADR reports were of possible causality followed by probable and certain as per WHO UMC and Naranjo causality scales. Only ten ADRs were preventable and one reaction (Tamoxifen-induced neuropathy) was eligible for signal detection. Disproportionality analysis using a 2x2 contingency table showed insignificant signal detection using the Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR).</p><p><strong>Conclusion: </strong>Analysis of ADRs from an ADR Monitoring center functioning in a tertiary care hospital shows antineoplastic drugs to be the most common drugs associated with adverse drug reactions, with rash being the most common adverse effect. The majority of the ADRs were not preventable. No Signals of Disproportionate Reporting (SDR) were detected in our study.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863317987241015034413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Adverse Drug Reactions (ADR) are one of the essential causes of hospital admissions and pose a significant clinical and economic burden on the healthcare system. The Adverse Drug Reaction Monitoring Centre (AMC) in JIPMER functioning under the Pharmacovigilance Programme of India (PvPI) plays a vital role in ensuring medication safety by routinely detecting and monitoring ADRs. Hence, this study aimed to assess the characteristics of ADR reported from 2010 to 2020 in AMC JIPMER and to detect signals, if any.

Objectives: To study the characteristics of Adverse Drug Reactions (ADR) reported to a regional ADR monitoring center from 2010 to 2020 and to detect signals of disproportionate reporting (SDRs) if any from the reported ADRs.

Materials and methods: A total of 6007 ADR reports with a single suspect drug were included for analysis from 2010 to 2020. The characteristics of these reports, including patient's age and gender, Number and percentage of ADRs, the causality of ADR using WHO UMC (World Health Organization-Uppsala Monitoring Scale), the seriousness of the ADR, and outcome were collected from the ADR reports. MedDRA (Medical Dictionary for Regulatory Activities) Preferred Terms (PT) were used to classify adverse drug reactions. Causality analysis using the Naranjo Algorithm and Preventability using Modified Schumock and Thornton criteria were performed for the ADRs. The number and percentage of severe ADRs were analyzed. The System Organ class of all the ADRs was enumerated. ADRs not mentioned in the US FDA (United States Food and Drug Administration) product label (unlabelled reactions) were documented. Unlabeled reactions with ≥3 ADR reports were included for signal detection by disproportionality analysis.

Results: Antineoplastic drugs, followed by antimicrobials, anticonvulsants, Anti snake venom, and NSAID were the most common drugs implicated in ADRs. Skin and subcutaneous tissue disorders were the most common System Organ Class (SOC) involved in the ADRs. Among the 6007 reports, 19.2% were serious ADRs. Most of the ADR reports were of possible causality followed by probable and certain as per WHO UMC and Naranjo causality scales. Only ten ADRs were preventable and one reaction (Tamoxifen-induced neuropathy) was eligible for signal detection. Disproportionality analysis using a 2x2 contingency table showed insignificant signal detection using the Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR).

Conclusion: Analysis of ADRs from an ADR Monitoring center functioning in a tertiary care hospital shows antineoplastic drugs to be the most common drugs associated with adverse drug reactions, with rash being the most common adverse effect. The majority of the ADRs were not preventable. No Signals of Disproportionate Reporting (SDR) were detected in our study.

2010 年至 2020 年向药物不良反应监测中心报告的药物不良反应 (ADR) 的回顾性观察研究。
背景:药物不良反应(ADR)是导致入院治疗的主要原因之一,给医疗保健系统造成了巨大的临床和经济负担。在印度药物警戒计划(PvPI)下运作的 JIPMER 药物不良反应监测中心(AMC)通过常规检测和监测 ADR,在确保用药安全方面发挥着至关重要的作用。因此,本研究旨在评估 JIPMER 药物警戒中心 2010 年至 2020 年报告的药物不良反应的特征,并检测可能存在的信号:研究 2010 年至 2020 年向地区药物不良反应监测中心报告的药物不良反应(ADR)的特征,并从报告的药物不良反应中检测是否存在比例失调报告(SDR)信号:在 2010 年至 2020 年期间,共纳入 6007 份涉及单一可疑药物的 ADR 报告进行分析。从 ADR 报告中收集了这些报告的特征,包括患者的年龄和性别、ADR 的数量和百分比、使用 WHO UMC(世界卫生组织-乌普萨拉监测量表)计算的 ADR 因果关系、ADR 的严重程度以及结果。采用 MedDRA(监管活动医学词典)首选术语(PT)对药物不良反应进行分类。使用纳兰霍算法对不良反应进行因果关系分析,并使用修改后的舒莫克和桑顿标准对不良反应进行可预防性分析。对严重 ADR 的数量和百分比进行了分析。列举了所有 ADR 的系统器官类别。记录了美国 FDA(美国食品和药物管理局)产品标签中未提及的 ADR(无标签反应)。通过比例失调分析,将 ADR 报告≥3 例的无标签反应纳入信号检测:抗肿瘤药物、抗菌药、抗惊厥药、抗蛇毒药和非甾体抗炎药是最常见的不良反应药物。皮肤和皮下组织疾病是药物不良反应中最常见的系统器官分类(SOC)。在 6007 份不良反应报告中,19.2% 为严重不良反应。根据世卫组织 UMC 和纳兰霍因果关系量表,大多数 ADR 报告都有可能的因果关系,其次是可能和确定的因果关系。只有 10 例 ADR 是可预防的,1 例反应(他莫昔芬诱发的神经病变)符合信号检测条件。使用 2x2 或然率表进行的比例失调分析表明,使用报告几率比(ROR)和比例报告比(PRR)进行信号检测的结果并不显著:对一家三甲医院药物不良反应监测中心的药物不良反应分析表明,抗肿瘤药物是最常见的药物不良反应相关药物,皮疹是最常见的不良反应。大多数药物不良反应是无法预防的。在我们的研究中没有发现不相称报告信号(SDR)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current drug safety
Current drug safety PHARMACOLOGY & PHARMACY-
CiteScore
2.10
自引率
0.00%
发文量
112
期刊介绍: Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信